With the life expectancy of individuals in the developed nations reaching historic highs, the incidence of dementia within the aging population is also increasing. Of the known causes of dementia, the major culprit is Alzheimer's disease (AD). The numbers of individuals suffering from AD is expected to nearly triple over the next 35 years unless medical science can identify better methods for diagnosing and treating AD. Fortunately, proteomics technologies have not only rapidly matured in the past few decades but also have been effectively applied so that the biomarkers of AD can be more effectively vetted and analyzed. The effectiveness of the technologies described in this paper enable the efficacy of drugs aimed at treating AD to be tested much faster than the previously possible and enable the more accurate selection of patients that are suitable for clinical trials.